Streetbeat News

Revenues

NRIX

Analyst ratings for Nurix Therapeutics (NASDAQ:NRIX) over the past three months show a mix of bullish to bearish sentiments, with a recent average price target of $23.43, up from $22.75. The company, focusing on novel treatments for cancer and immune disorders, has seen varied analyst actions, including maintaining, raising, and lowering ratings and price targets. Despite impressive revenue growth, Nurix faces challenges in net margin, ROE, and ROA, but maintains a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:01 pm

DADA

Recent analyst ratings for Dada Nexus (NASDAQ:DADA) show a mix of bullish and neutral perspectives, with a notable decline in the average 12-month price target to $3.6, down 53.85% from the prior average. Analysts from Jefferies, New Street Research, Daiwa Capital, and Mizuho have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Dada Nexus, a leading crowdsourced delivery service in China, has shown a positive revenue trend with a 20.44% growth rate as of September 30, 2023, but faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:00 pm

SATS

EchoStar (NASDAQ:SATS) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target is now $20.5, down 9.57% from the previous average, with recent actions including both lowered and raised price targets by analysts from JP Morgan, UBS, and TD Cowen. EchoStar's financial performance shows challenges in revenue growth, profitability, and asset utilization, despite a prudent debt management strategy. The company, known for its satellite television and internet services, is focusing on expanding its wireless business.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:00 pm

VEL

Velocity Financial (NYSE:VEL) has received diverse analyst ratings over the last three months, with a recent shift towards more bullish perspectives. Four analysts have updated their ratings, showing a trend of increased price targets, with the current average target at $17.88, reflecting a 16.25% increase from the previous average of $15.38. The company's financial performance has been strong, with significant revenue growth, high net margin, and ROE, although its debt-to-equity ratio is higher than the industry average.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:00 pm

SPY

The White House projects an increase in receipts from 16.5% of GDP in FY23 to 18.7% in FY25, reaching 20.3% by FY34. Public debt is expected to rise from 97.3% of GDP in FY23 to 102.2% in FY25, and further to 105.6% by FY34. Real interest rates are forecasted at 1.2% in FY25, with an average of 1.3% over the FY 2025-2034 period. U.S. real GDP growth is estimated at 1.8% in 2025, 2.0% in 2028, and 2.2% in 2034, based on November forecasts.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 4:18 pm

SPY

The White House's budget proposal for FY25 forecasts a deficit of $1.781 trillion, a slight decrease from the previous year's $1.859 trillion, and $1.694 trillion for FY23. Over the decade from FY25 to FY34, the cumulative deficit is estimated at $16.297 trillion, significantly lower than the CBO's forecast of $20.016 trillion. The deficit as a percentage of GDP is expected to be 6.1% in FY25, decreasing from 6.6% in FY24, with an average of 4.6% over the decade.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 4:17 pm

EHAB

Analysts have mixed views on Enhabit (NYSE:EHAB), with recent ratings ranging from bullish to indifferent. The average 12-month price target is now $11.5, down from $13.50, reflecting a 14.81% decline. Analysts from TD Cowen, UBS, and Jefferies have adjusted their ratings and price targets, indicating varied expectations for the company's performance. Enhabit's financials show a -2.79% revenue decline over 3 months, a net margin of -0.93%, and a debt-to-equity ratio of 0.91, suggesting challenges but also areas of strong performance.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 4:01 pm

BRCC

Analysts have mixed views on BRC Inc (NYSE:BRCC), with recent ratings showing a shift towards a more neutral stance. The average 12-month price target has significantly increased to $7.19 from $3.50, indicating a positive outlook. BRC's financial performance shows strong revenue growth but challenges in profitability and debt management. The company, serving premium coffee and merchandise to military and first responders, has seen its market capitalization fall below industry benchmarks.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 4:00 pm

SQ

Block (NYSE:SQ) has received diverse analyst ratings over the last three months, with a total of 15 analysts offering evaluations ranging from bullish to bearish. The average 12-month price target for Block is $88.93, marking a 13.29% increase from the previous average of $78.50. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and Block's performance. The company has shown impressive revenue growth of 24.13% as of December 31, 2023, but faces challenges in profitability and efficiency, with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 4:00 pm

COLD

Americold Realty Trust (NYSE:COLD) has received mixed analyst ratings over the last three months, with a shift towards a more cautious outlook. The average 12-month price target was reduced by 6.06% to $31.0. Analysts from Truist Securities, JP Morgan, Raymond James, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Americold, a major player in temperature-controlled warehouses, has seen a decline in revenue by -5.85% and faces challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 4:00 pm